Business Wire

Children and young people encounter multiple forms of gender-based violence – an online course produced by an international project coordinated by Tampere University helps to identify and prevent it

24.1.2022 13:05:00 EET | Business Wire | Press release

Share

Children and young people are exposed to a wide range of gendered violence. However, the phenomenon is poorly understood, which makes helping the victims difficult. The international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project, coordinated by Tampere University, produced an online course to help identify, prevent and address gender-based violence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005334/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University. (Photo: Business Wire)

How do you approach young people who experience discrimination based on their gender expression? How do you deal with offensive images of your student, for example, on social media? And how do you address sexual violence faced by children or young people? Violence against children and youths is often referred to as bullying, even when it is considered assault by the Criminal Code.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University.

Husso leads the international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project coordinated by Tampere University, which has just published a free online course on encountering gender-based violence at schools in English, Finnish and Swedish. The training is also produced in Croatian, Spanish and Catalan.

It is a research-based e-learning package that develops new skills for those working in education, social work and health services. The training is aimed specifically at professionals working with 13–19-year-old teenagers but is also suitable for use with younger and older students. The training looks at the phenomenon from the perspectives of the person experiencing violence, the perpetrator, bystanders, and professionals and experts.

Schools play a pivotal role

Schools play a key role in identifying and addressing violence. The social environment of schools provides an opportunity to learn interaction skills and offers a unique opportunity to influence the perceptions and behaviour of children and young people. At the same time, it enables awareness-raising and change towards more equal relationships and more ethical practices.

“Addressing violence is a prerequisite for promoting equality and sustainable development. This new online training provides tools for preventing, identifying, and addressing violence. It provides information on such issues as digital violence, the impact of violence, good practices and legislation on the subject," says Husso.

“Getting help for problems of violence depends on the problem first being identified and addressed,” she emphasises.

The EraseGBV project has researched gender-based violence and ethical agency in schools and education in Finland, Croatia and Spain. The research partners comprise Tampere University; the University of Zagreb; Blanquerna Ramón Llull University; the Centre for Education, Counselling and Research (CESI); and Conexus.

For more information and instructions on how to register, please see the link to further information and the online course: https://projects.tuni.fi/erasegbv/training-programme/

Photo: In her future projects, Associate Professor Marita Husso will focus on promoting nonviolence and sustainable wellbeing and exploring harmful ideological, institutional and affective practices related to violence. Photo by Hanna-Kaisa Hämäläinen

Tampere University

The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health, and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together, Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enquiries:
Associate Professor Marita Husso
Faculty of Social Sciences, Tampere University
marita.husso@tuni.fi, tel. +358503182510

University Researcher Satu Lidman
Faculty of Social Sciences, Tampere University
satu.lidman@tuni.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye